论文部分内容阅读
本文对比研究了氨苄青霉素与氨苄青霉素·舒巴克坦(Unasyn)在10名健康志愿者的血清杀菌活性(SBA)。结果表明Unasyn3g(含氨苄青霉素2g,舒巴克坦1g)静脉注射后,对产酶耐氨苄青霉素金葡菌、奇异变形杆菌、乙酸钙不动杆菌和克雷白肺炎杆菌峰时SBA(1∶8～≥1∶32)非常显著高于单用氨苄青霉素2g(SBA<1∶1～1∶2);应用Unasyn对上述菌株SBA≥1∶8者达50～100％,而单用氨苄青霉素SBA均在1∶8以下。Unasyn对耐药大肠杆菌和阴沟肠杆菌的杀菌活性稍弱,但仍显著强于单用氨苄青霉素。提示舒巴克坦与氨苄青霉素联用对于产酶耐药的常见病原菌的体内杀菌活性均显示了增效作用。
This article compared the serum bactericidal activity (SBA) of ampicillin with ampicillin-sulbactam (Tenasyn) in 10 healthy volunteers. The results showed that Unasyn3g (containing ampicillin 2g, sulbactam 1g) after intravenous injection, the resistance to ampicillin-resistant Staphylococcus aureus, Proteus mirabilis, Acinetobacter calcoaceticus and Klebsiella pneumoniae peak SBA (1: 8 ~> 1: 32) was significantly higher than single ampicillin 2g (SBA <1: 1 ~ 1: 2); Unasyn application of the above strains SBA ≥ 1: 8 were 50 to 100%, while only ampicillin SBA All below 1: 8. Unasyn had a slightly weaker bactericidal activity against resistant E. coli and Enterobacter cloacae but remained significantly stronger than ampicillin alone. It is suggested that the combination of sulbactam and ampicillin shows a synergistic effect on the bactericidal activity in vivo of the common pathogens that produce enzyme resistance.